Trials / Not Yet Recruiting
Not Yet RecruitingNCT07504263
Phase 1/2a Study of RP-001 in Participants With Advanced Malignancies
An Open-label, Multicenter, Phase 1/2a Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of RP-001 in Participants With Advanced Malignancies
- Status
- Not Yet Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 66 (estimated)
- Sponsor
- Recurv Pharma Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Phase 1/2a Study of RP-001 in participants with Advanced Malignancies
Detailed description
An Open-label, Multicenter, Phase 1/2a Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of RP-001 in Participants with Advanced Malignancies
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RP-001 | A new class of Taxane. |
Timeline
- Start date
- 2026-04-23
- Primary completion
- 2027-12-01
- Completion
- 2028-04-01
- First posted
- 2026-03-31
- Last updated
- 2026-03-31
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07504263. Inclusion in this directory is not an endorsement.